Other

Johnson Matthey Inc.

Thomas Jefferson University

Oxford University Innovation Limited

United Therapeutics Corporation

Sky High, LLC

Smithkline Beecham Corporation

Donald H Picker

James G Heffernan

Paul C Hydes

Raymond A Dwek

David Aaron Schwartz

John D Bradley

Timothy Michael Block

Gary S Jacob

Terry D Butters

Frances M Platt

Nicole Zitzmann

Ian C Bathurst

Anand Mehta

Matthew W Foehr

George W J Fleet

Michael J Cleare

J Graham Goddard

John G Goddard

Sandra Carrouee

Samiul R Umansky

Steven Price

Jac C Wijkmans

David Durantel

Edward A Boyd

Anthony D Baxter

Michael J Abrams

Alison Mary Badger

Christen M Giandomenico

Samuil R Umansky

Jean F Vollano

Christopher K Mirabelli

Geoffrey W Henson

Anthony J Serino

Michael W Lord

Edward Rosenberg

William H Tamblyn

Michael J DiMartino

James W Dorman

Elaine N Cheeseman

Samull R Umansky

Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C-Calkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.

Long chain N-alkyl compounds and oxa-derivatives thereof

Long chain n-alkyl compounds and oxa-derivatives thereof

The invention provides anti-apoptotic compositions containing lysophosphatidic acids and methods for making and using the compositions. Such compositions may also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.

Compositions containing lysophosphotidic acids which inhabit apoptosis and uses thereof

The invention provides anti-apoptotic compositions lysophosphatidic acids and methods for making and using the compositions. Such compositions can also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.

Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof

The present invention provides therapeutic compositions containing lysophosphatidic acids, methods for making the compositions, and methods of use thereof.

Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof

The present invention provides therapeutic compositions containing lysophosphotidic acids, methods for making the compositions, and methods of using the compositions in the preservation and treatment of organs.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an effective amount of an azaspirane derivative, a method of treating an animal in need of immunomodulation which comprises administering to such animal an effective amount of an azaspirane derivative, and certain azaspirane derivatives.

Immunomodulatory azaspiranes

Platinum co-ordination compounds comprising at least one amine ligand and a functional group remotely bonded to the amine ligand, which functional group may be linkable to a monoclonal antibody to provide a moiety which stabilizes the antibody against in vivo hydrolysis.

Monoclonal antibody - platinum co-ordination compound complex

A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilizes the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.

Monoclonal antibody-platinum co-ordination compound complex

The present invention relates to a method of potentiating radiation therapy using Co(III) complexes of water soluble, synthetic meso-substituted porphyrins. The method results in the sensitization of both well oxygenated (oxic) and oxygen deficient (hypoxic) tumor cells.

Radiation sensitizers

A composition comprising a pharmaceutically acceptable polysaccharide carrier which has been chemically activated and then linked to platinum in either a +2 or +4 oxidation state through a bidentate oxygen-containing ligand including an amine group coupled to the activated polysaccharide. The composition may be used to link platinum metal remotely to a monoclonal antibody via the oxygen-containing ligand and the polysaccharide carrier such as dextran. The composition is optionally radiolabeled.

Macromolecular platinum antitumor compounds

Platinum co-ordination compounds

A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilises the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.

A catalyst composition comprising a PGM complex bound to a carboxylated polymer containing not more than 5 mol equivalents of carboxylate groups per gram of polymer.

Supported catalyst

Coordination compounds for use in therapy, the compounds having the general empirical formula

Combination modality cancer therapy

Growing community of inventors

Narbert, PA, United States of America

Donald H Picker